Team Impulse

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

Retrieved on: 
Friday, January 26, 2024
Patient, PST, Prostate cancer, Carcinoma, Bladder cancer, ASCO, Team Impulse, Society, TSC1, Urethra, GU, TSC2, Progress, Kidney cancer, Cancer

LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.

Key Points: 
  • LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.
  • Abstract and poster presentation details are below:
    Date/Time: January 26, 2024 – 11:30 – 1:00 pm; 5:45 – 6:45 pm PST
    In a large real-world database of patients with advanced cancer, 1,828 (4.0%) of the 46,068 patients with GU cancers had at least one inactivating alteration in TSC1 or TSC2
    TSC1 and/or TSC2 inactivating alterations were present in 9.2% of patients with bladder cancer, 6.4% of patients with kidney cancer, and 0.6% of patients with prostate cancer
    Aadi is also presenting an encore Trials-in-Progress (TiP) poster from the ongoing PRECISION 1 study.
  • Session Title: Trials in Progress Poster Session C: Renal Cell Cancer: Adrenal, Penile, Urethral and Testicular Cancers
    Date/Time: January 27, 2024 – 7:00 – 8:00 am; 11:30 am – 1:00 pm PST

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

Retrieved on: 
Friday, January 19, 2024
MSI, Patient, Pancreas, Cancer, Research, MSS, ASCO, Diagnosis, Lunch, Team Impulse, Society, TMB, TSC1, NET, Gastrointestinal tract, Liver, TSC2, Progress, Colorectal cancer, GI, Pharmaceutical industry

LOS ANGELES, Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA. 

Key Points: 
  • LOS ANGELES, Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA.
  • Abstract and poster presentation details are below:
    In a large real-world database of patients with advanced cancer, 1,898 (1.4%) of the 138,671 patients with GI cancers harbored at least one known or likely inactivating alteration in TSC1 or TSC2
    TSC1 and/or TSC2 inactivating alterations were present in 6.8% of liver cancers, 1.6% of colorectal cancers, and 0.5% of pancreatic cancers
    Most TSC1 and/or TSC2 inactivating alterations in liver and pancreatic cancers occurred in the context of low TMB and MSS tumors; whereas increased TMB and MSI signatures were enriched in colorectal cancer with TSC1 and/or TSC2 alterations
    Limitations of this exploratory, real-world study include the timing of sampling (at initial diagnosis vs disease progression) and the absence of clinically matched outcomes data.
  • More research is needed to understand the clinical and prognostic implications of these data
    Aadi is also presenting Trials-in-Progress (TiP) posters from its PRECISION 1 and NET clinical studies.
  • Session Title: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
    Title: "A phase 2, study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lunch, or pancreas"
    Session Title: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Fosun Pharma USA Announces Abstract to be Presented at IASLC 2023 North America Conference on Lung Cancer (NACLC)

Retrieved on: 
Tuesday, November 28, 2023
Health equity, Team Impulse, NACLC, International Association, Innovative Medicines Canada, Patient, Carcinoma, Medical Affairs Bureau, SCLC, Conference, Diagnosis, Lung cancer, Extensive stage, Pharmaceutical industry

PRINCETON, N.J., Nov. 28, 2023 /PRNewswire/ -- Fosun Pharma USA Inc. ("Fosun Pharma USA") announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer's (IASLC) 2023 North America Conference on Lung Cancer (NACLC), being held in Chicago, Illinois, Dec. 1 - 3, 2023.

Key Points: 
  • PRINCETON, N.J., Nov. 28, 2023 /PRNewswire/ -- Fosun Pharma USA Inc. ("Fosun Pharma USA") announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer's (IASLC) 2023 North America Conference on Lung Cancer (NACLC), being held in Chicago, Illinois, Dec. 1 - 3, 2023.
  • "Our PIs are excited to present their poster on the design of the ASTRIDE Trial in Progress (TiP), which is an important milestone for the lead investigators and authors," said Stan Lechpammer, Vice President, Medical Affairs, Innovative Medicines, Fosun Pharma USA.
  • "This presentation provides greater insight into the ASTRIDE trial that investigates serplulimab as a potentially new therapeutic option for extensive-stage (ES) small-cell lung cancer patients (SCLC).
  • SCLC is an aggressive malignancy, with the majority of patients presenting with extensive-stage disease at initial diagnosis.

Flamingo Therapeutics Announces Poster Presentation at ESMO Congress 2023

Retrieved on: 
Tuesday, October 17, 2023
MD, ESMO, Congress, Poster, Doctor of Philosophy, Team Impulse, Flamingo

LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, Oct. 17, 2023 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced the presentation of a "Trials-in-Progress", or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.

Key Points: 
  • LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, Oct. 17, 2023 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced the presentation of a "Trials-in-Progress", or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.
  • Members of the Flamingo leadership team, Andrew Denker, MD, PhD, Chief Medical Officer, and Morgane Perdomini, PhD, Director Development, will be present at the congress.
  • Details of the TiP poster presentation are below:
    More details can be found on the ESMO website.

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023
Congress, Merck & Co., University of Frankfurt Institute for Social Research, Senior, Merck Sharp & Dohme Federal Credit Union, Business, Fast track (FDA), Survival, LAG-3, Abstract, Pembrolizumab, NSCLC, ASX, CSO, OS, Mini, Radiation, Lung cancer, Cancer, Autoimmune disease, IMM, Patient, European Society for Medical Oncology, ESMO, Oncology, Webcast, CMO, Team Impulse, All-comers track meet, Merck, TPS, Overalls, Research, Immutep, ICO, AEDT, Pharmaceutical industry

SYDNEY, AUSTRALIA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the publication of abstracts with data from the TACTI-002 and INSIGHT-003 trials in 1st line non-small cell lung cancer (1L NSCLC) at the 2023 European Society for Medical Oncology (ESMO) Congress.

Key Points: 
  • Notably, new updated data from TACTI-002, including more mature Overall Survival (OS) results, will be presented by Dr. Enric Carcereny, Catalan Institute of Oncology, Badalona (ICO), during a Mini Oral session (#1312MO) at ESMO Congress 2023 on Saturday, October 21, 2023, at 9:05 AM CEST.
  • The data in the INSIGHT-003 abstract, with a cut-off date of 18 April 2023, showed a promising 67% overall response rate.
  • The event will feature Immutep CEO Marc Voigt, CSO Dr Frederic Triebel, CMO Dr Florian Vogl, and Christian Mueller, Senior Vice President Strategic Development.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, September 20, 2023
Abstract, AACR, Genome, AADI, Patient, TSC2, Team Impulse, Foundation Medicine, Conference, TSC1, Breast cancer, Pharmaceutical industry

LOS ANGELES, Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that four abstracts have been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA.

Key Points: 
  • LOS ANGELES, Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that four abstracts have been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA.
  • The presentations include four posters: a Trials-in-Progress (TiP) update from the PRECISION1 trial in TSC1/2 alterations, two real-world clinical genomic analyses, and one preclinical study of nab-sirolimus combinations in breast cancer xenograft models.
  • Title: "Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient (pt) population using the Foundation Medicine genomic database"

Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Tuesday, August 8, 2023
FXR, Obesity, NASH, CML, Week, Cohort, GIPR, American Society of Clinical Oncology, Clinical trial, BCR-ABL, Research, Acute leukemia, THR, ASCO, DSM-IV codes, Administration, Team Impulse, DUET, American Diabetes Association, Fatty liver disease, Research and development, R, BMI, FDA, ADA, Society, Pharmaceutical industry, Cryptocurrency, Tern

FOSTER CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today reported financial results for the quarter ended June 30, 2023 and corporate updates.

Key Points: 
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026.
  • Research and Development (R&D) Expenses: R&D expenses were $14.2 million for the quarter ended June 30, 2023, as compared with $8.7 million for the quarter ended June 30, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $7.0 million for the quarter ended June 30, 2023, as compared with $5.4 million for the quarter ended June 30, 2022.
  • Net Loss: Net loss was $17.9 million for the quarter ended June 30, 2023, as compared with $13.9 million for the quarter ended June 30, 2022.

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Obesity, NASH, CML, McCormick Place, Cohort, Pharmacokinetics, Acute leukemia, ASCO, American Society of Clinical Oncology, Patient, Team Impulse, Annual general meeting, Fatty liver disease, Society, Safety, Pharmaceutical industry

FOSTER CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that the TERN-701 (HS-10382) trial-in-progress (TiP) abstract is now available on the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting website. The ASCO Annual Meeting will be held in person at McCormick Place in Chicago, Illinois, and online from June 2 - 6, 2023.

Key Points: 
  • FOSTER CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that the TERN-701 (HS-10382) trial-in-progress (TiP) abstract is now available on the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting website.
  • The ASCO Annual Meeting will be held in person at McCormick Place in Chicago, Illinois, and online from June 2 - 6, 2023.
  • The TiP abstract details that patient enrollment reached Cohort 3 of the Dose Escalation phase as of February 2023, with seven participating study sites in China.
  • The TiP poster highlights completion of enrollment of Cohort 5 as of April 2023.

Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Monday, May 15, 2023
Obesity, NASH, CML, GIPR, American Society for Pharmacology and Experimental Therapeutics, CT1, Clinical trial, Pharmacokinetics, Hope, BCR-ABL, Experiment, Acute leukemia, Hansoh Pharmaceutical, MRI, Administration, Team Impulse, Fatty liver disease, Tern, Poster, Research and development, R, Pharmacology, Society, Safety, ASPET, Rare-earth element, Pharmaceutical industry, Medical imaging, Cryptocurrency

FOSTER CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today reported financial results for the first quarter ended March 31, 2023 and corporate updates.

Key Points: 
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026.
  • Research and Development (R&D) Expenses: R&D expenses were $17.1 million for the quarter ended March 31, 2023, as compared with $8.1 million for the quarter ended March 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $7.1 million for the quarter ended March 31, 2023, as compared with $5.7 million for the quarter ended March 31, 2022.
  • Net Loss: Net loss was $21.5 million for the quarter ended March 31, 2023, as compared with $13.8 million for the quarter ended March 31, 2022.

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Thursday, May 11, 2023
Therapy, CAB, LMS, Head, G&A, Lung cancer, Conditional, ASCO, CTC, Soft tissue, American Society of Clinical Oncology, AXL, Team Impulse, SAN, Annual general meeting, Webcast, Recurrence, R, PD-1, Research, FDA, Adenocarcinoma, Society, Food, Pharmaceutical industry, Vaccine, Platinum, Cryptocurrency, NSCLC, Patient

Research and development (R&D) expenses were $21.7 million for the quarter ended March 31, 2023 compared to $16.9 million for the same quarter in 2022.

Key Points: 
  • Research and development (R&D) expenses were $21.7 million for the quarter ended March 31, 2023 compared to $16.9 million for the same quarter in 2022.
  • General and administrative (G&A) expenses were $7.2 million for the quarter ended March 31, 2023 compared to $7.4 million for the same quarter in 2022.
  • Net loss for the first quarter ended March 31, 2023 was $27.5 million compared to a net loss of $24.3 million for the same quarter in 2022.
  • The management of BioAtla, Inc. will host a conference call and webcast for the investment community today, May 11, 2023, at 4:30 pm Eastern Time.